Researchers reviewed 26 human studies on cannabinoids for skin conditions and found promising results for inflammatory disorders—specifically, CBD and THC showed real benefits for pain relief in epidermolysis bullosa (a blistering condition), and certain cannabinoid compounds helped with systemic sclerosis and dermatomyositis. However, the evidence is still early-stage; we need more research to nail down proper doses, confirm safety, and understand long-term effects.

Scientists searched medical databases for human studies published between 1965 and October 2020, focusing on cannabinoids used for skin conditions. They narrowed down from 248 initial studies to 26 that met their criteria, looking at both topical and systemic (oral/sublingual) cannabinoid treatments.

Funding not disclosed in abstract